

## Key Figures Fresenius Group (US GAAP; unaudited)

Due to the separate financing of Fresenius SE and Fresenius Medical Care, we have prepared the following overview for information purposes for our debt investors. The overview includes key figures of the Fresenius Group before consolidation of Fresenius Medical Care as of June 30, 2009.

Earnings of Fresenius SE include dividends of € 62 million in 2009 and € 58 million in 2008, according to Fresenius SE's holding of ordinary shares in Fresenius Medical Care (as of December 31, 2008: 36.3 %).

in million €	H1 2009 (unaudited)	H1 2008 (unaudited)
<b>Sales</b>	<b>2,918</b>	2,357
<b>EBITDA</b>	<b>552</b>	391
Depreciation and amortization	-113	-87
<b>EBIT</b>	<b>439</b>	304
Net interest	-183	-59
Other financial result	43	0
Income before income taxes	299	245
Income taxes	-60	-55
less noncontrolling interest	-15	-14
<b>Net income attributable to Fresenius SE, adjusted <sup>1)</sup></b>	<b>190</b>	176
<b>Net income attributable to Fresenius SE</b>	<b>224</b>	176

in million €	H1 2009	H1 2008
Investment in property, plant and equipment (gross)	96	108
Acquisitions (gross)	93	204
Operating cash flow	334	277
Debt <sup>2)</sup>	4,733	4,710
Net debt <sup>2)</sup>	4,517	4,499
Net debt/EBITDA <sup>2) 3)</sup>	4.1	4.5
EBITDA/Interest <sup>2) 3)</sup>	3.0	2.9

<sup>1)</sup> adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) relating to the acquisition of APP Pharmaceuticals

<sup>2)</sup> 2008: December 31

<sup>3)</sup> 2008 pro forma APP